微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: A Novartis drug cut inflammation. Can it improve heart outcomes?
RSS 官方收录 · 可信分层展示
关键摘要
诺华新药pacibekitug在II期试验中显著降低炎症标志物
- pacibekitug靶向IL-6蛋白，属抗体类药物
- TRANQUILITY II期研究显示剂量依赖性炎症标志物下降
- 数据在欧洲心脏病学会年会公布
AI 摘要 · 来源可核验
正文提要
A newly acquired Novartis drug successfully lowered signs of inflammation in a midstage study, as experts wait to hear how the company plans to advance the drug as a potential cardiovascular treatment.
In the Phase 2 TRANQUILITY study, the drug, pacibekitug, led to sustained decreases in biomarkers of inflammation, according to results presented Saturday at the European Society of Cardiology’s annual meeting in Munich. Investigators reported a dose-dependent drop in biomarker levels on certain measures, meaning higher doses led to greater reductions, a sign the drug is having an effect.
Pacibekitug is an antibody that targets IL-6, or interleukin-6, a protein involved in regulating immune responses.